Billionaire Stanley Druckenmiller’s New Stock Picks Include AIG
Even though the information in 13F filings is several weeks old by the time it is released, there are a number of ways for investors to at least get some contributions from analyzing...
Posts Tagged ‘Johnson & Johnson (JNJ)’
Why Investors Should Love Celgene Corporation (CELG)’s Apremilast
Celgene Corporation (NASDAQ:CELG) shareholders didn't have to wait long for good news in 2013. On Jan.
Healthcare Giant’s Giant Drug: Johnson & Johnson (JNJ)
Dow-30 component Johnson & Johnson (NYSE:JNJ) is a giant healthcare company, with exposure to the consumer products, medical devices, and pharmaceuticals arenas.
Is Abbott Laboratories (ABT)’s Universal Microbe Detector a Big Deal?
I think I have uncovered the real reason why Abbott Laboratories (NYSE:ABT) decided to spin off its pharmaceutical division into AbbVie Inc (NYSE:ABBV).
Merck & Co., Inc. (MRK): A Global Health Care Giant Doling Out a Massive Dividend
A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a tremendous way to gain a detailed and thorough perspective on a company ...
9.1% of TB Drugs Fail Quality Control: Roche Holding Ltd. (ROG)
In the 1990s, New York spent over a billion dollars to battle an outbreak of tuberculosis, and now with almost one in ten doses of common anti-TB drugs failing to meet basic standards...
5 Smart Money Moves for Retirees: The Coca-Cola Company (KO), The Procter & Gamble Company (PG)
With times as tough as they've been in recent years, it's never been more important to keep your personal finances in good shape.
Down 85%! Why Affymax, Inc. (AFFY) is Getting Crushed This Morning
Look out below Affymax, Inc. (NASDAQ:AFFY) investors.
5 Can’t-Miss Health-Care Events This Week: Zogenix, Inc. (ZGNX), Ariad Pharmaceuticals, Inc. (ARIA)
Normally we have a nice blend of health-care events to take notice of each week.
The Dow Rally Nobody Believed In: Johnson & Johnson (JNJ) and More
The Dow Jones Industrial Average breached the 4,000-point barrier for the first time in its history on Feb. 23, 1995, closing at 4,003.33.
Pfizer Inc. (PFE): A Global Biotechnology Company in its 164th Year
A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a great way to gain a detailed and thorough perspective on a company and its...
More Upside on this Biotechnology Giant: Celgene Corporation (CELG)
The Food and Drug Administration added Celgene Corporation (NASDAQ:CELG)’s Pomalyst to the list of approved drugs last Friday.
Dendreon Corporation (DNDN) Earnings: An Early Look
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
MAKO Surgical Corp. (MAKO) Earnings: An Early Look – Johnson & Johnson (JNJ), Stryker Corporation (SYK)
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
The Most Popular Healthcare Stocks Among Hedge Funds Include Pfizer
Even with the delay inherent in 13F filings (these filings disclose many of a hedge fund or other investor’s long equity positions at the end of a quarter, but are not released...
This News Should Get Your Blood Pumping: ABIOMED, Inc. (ABMD), Amgen, Inc. (AMGN)
Following the close of the bell yesterday, ABIOMED released a statement announcing that U.S.
The Not-So-Hip Trend at Johnson & Johnson (JNJ)
If there's one company that nearly every investor knows in the health care arena, it's Johnson & Johnson (NYSE:JNJ).
Is AbbVie Inc (ABBV) Wasting Your Money?
Stock buybacks are generally considered a bullish signal on Wall Street.
Pomalyst Takes the Stage: Celgene Corporation (CELG), Johnson & Johnson (JNJ), Onyx Pharmaceuticals, Inc. (ONXX)
Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year.
You Will Love These Stocks More in 2013: General Electric Company (GE), Johnson & Johnson (JNJ)
I am always on the hunt to pick up those stocks which the investment managers are betting upon aggressively.
Has Johnson & Johnson (JNJ) Become the Perfect Stock?
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Can JAK Inhibitors Challenge Biologics?: Johnson & Johnson (JNJ) and More
When the word "biotechnology" gets thrown around in the pharmaceutical industry, it often implies the biomanufacturing of biologic drugs, such as therapeutic proteins.
Where is The Procter & Gamble Company (PG) Going?
The results of the second quarter of fiscal year 2013 for The Procter & Gamble Company (NYSE:PG) can indeed be a source of joie de vivre, the zest for life often extolled in...
Whoa! These 3 Stocks Are on the Ball: Pharmacyclics, Inc. (PCYC)
With the president calling for new initiatives on the federal minimum wage, immigration, gun control, and early childhood education, the Dow Jones Industrial Average was filled...
Can Johnson & Johnson (JNJ)’s Zytiga Build on a Historic 2012?
Johnson & Johnson (NYSE:JNJ) may offer well-known personal-care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market-leading therapeutic...
Strong Long Term Prospects With This Defensive Growth Play: Perrigo Company (PRGO)
Perrigo Company (NASDAQ:PRGO) is a company exposed to some very favorable trends in health care, and I would expect its strong performance to continue.
The FDA Made Biotech Investing Harder (But More Lucrative): Johnson & Johnson (JNJ)
For instance, it's hard to make money on shoo-in Food and Drug Administration approvals. The approval is already reflected in the price.
Has Avanir Pharmaceuticals, Inc. (AVNR) Become the Perfect Stock?
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
The Dow’s Most Diversified Winners: Johnson & Johnson (JNJ) and More
The 30 companies among the Dow Jones Industrials all have a pedigree as the leaders in their respective fields, having found success among their peers.
Does the Arthritis Market Have Growing Pains? – AbbVie Inc (ABBV)
Research firm Decision Resources predicts that the rheumatoid arthritis market will modestly grow to $15 billion in the next decade.
This Week in Biotech: AbbVie Inc (ABBV) and More
With the SPDR S&P Biotech Index up 20% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Pharmacyclics, Inc. (PCYC) Still on a Roll After Earnings Results
It's been a big week for Pharmacyclics, Inc. (NASDAQ:PCYC).
3 Humongous Health-Care Stocks This Week: Pharmacyclics, Inc. (PCYC) and More
Sweet! No, I'm not talking about leftover Valentine's Day candy and chocolates. Sweet is the operative word for the returns attained by several health-care stocks this week.
Merck & Co., Inc. (MRK)’s Dynamic Duo
Merck & Co., Inc. (NYSE:MRK) lost blockbuster asthma drug Singulair off the patent cliff last year, and the sales plunge quickly followed.
A Portfolio of Safety Stocks: General Mills, Inc. (GIS), Sysco Corporation (SYY), and More
A few days ago, I started searching for the best Safety Stocks. These are stocks that I feel will hold up well in the face of a bad economy or recession. They make products...
This Just In: Upgrades and Downgrades – Dendreon Corporation (DNDN) and More
At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." Today, we'll show you ...
Is the Pharma Industry Facing Pharmageddon? Pfizer Inc. (PFE) and More
The pharmaceuticals industry has always been one of the riskiest in the market.
Buy, Sell, or Hold: MAKO Surgical Corp. (MAKO)
When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons, and decide whether it's possible upside outweighs its risks.
Is Johnson & Johnson (JNL) a Future Blockbuster?
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic...
Merck & Co., Inc. (MRK)’s Crash of a Titan
Merck & Co., Inc. (NYSE:MRK)'s blockbuster asthma and allergy treatment Singulair fell off patent last year -- wiping more than 60% of revenue off the company's top line.
Can Johnson & Johnson (JNJ) Hold Its Ground in the Multiple Myeloma Market?
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic...
More Good News for Celgene Corporation (CELG)
As expected, the U.S. Food and Drug Administration granted approval on Feb. 8 for Celgene Corporation (NASDAQ:CELG)'s Pomalyst in treating patients with multiple myeloma.
Has Elan Corporation, plc (ADR) (ELN) Become the Perfect Stock?
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Will Johnson & Johnson (JNJ) Win Approval for Its Diabetes Drug?
In addition to its well-known personal-care products such as Listerine and Neutrogena, Johnson & Johnson (NYSE:JNJ) boasts an impressive portfolio of market-leading therapeutic...
Celgene Corporation (CELG): Still Revving Up With Revlimid
What a roll Celgene Corporation (NASDAQ:CELG) has been on lately. The company has experienced success after success in recent months.
Allergan, Inc. (AGN): No Sign of a Slowdown at This Recession Resistant Company
I must confess I am finding the current market to be one of the most frustrating periods of my investing life.
How Far Can This Blockbuster Take Johnson & Johnson (JNJ)?
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market-leading therapeutic...
Eli Lilly & Co. (LLY): If You’re Going to Fail, Fail Quickly
It's not particularly surprising given that the drug failed a phase 3 trial in December, but it's still disappointing for a company that could really use a positive result.
The Expense Of Diabetes: Is It Worth It? Eli Lilly & Co. (LLY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT)
With studies showing 33% of Americans with diabetes or pre-diabetes, it is obvious that the industry should be booming.
